Bratkowski

Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron

Retrieved on: 
Tuesday, September 13, 2022

Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection, said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio.

Key Points: 
  • Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection, said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio.
  • Since its conception in 2018, Nura Bio has been steadily growing a differentiated, small molecule pipeline focused on targets implicated in driving axon degeneration and neuroinflammation in neurological diseases.
  • Nura Bios lead program, the SARM1 inhibitor program is currently in IND-enabling studies with the goal of entering First-in-Human trials in early 2023.
  • At Nura Bio we envision a world where the diagnosis of a neurological disorder comes with the hope of a cure.